Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor

References

• TraversJGKamalFARobbinsJYutzeyKEBlaxallBCCardiac fibrosis: the fibroblast awakensCirc Res20161186 1021 104026987915
   PubMed Web of Science ®Google Scholar
• HillJAOlsonENCardiac plasticityN Engl J Med200835813 1370 138018367740
   PubMed Web of Science ®Google Scholar
• KrenningGZeisbergEMKalluriRThe origin of fibroblasts and mechanism of cardiac fibrosisJ Cell Physiol20102253 631 63720635395
   PubMed Web of Science ®Google Scholar
• BaiFPangXFZhangLHAngiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44–hyaluronan interaction in rats with hypertension and myocardial fibrosisLife Sci2016153 141 15227085217
   PubMed Web of Science ®Google Scholar
• CrowleyMJPowersBJMyersERMcBroomAJSandersGAngiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritizationAm Heart J20121635 777 78222607854
   PubMed Web of Science ®Google Scholar
• ZhangLHPangXFBaiFPreservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1/AT2 receptor expression and angiotensin-converting enzyme 2 activity in rat heartCardiovasc Drugs Ther2015293 243 25525994830
   PubMed Web of Science ®Google Scholar
• JonesESVinhAMcCarthyCAGaspariTAWiddopREAT2 receptors: functional relevance in cardiovascular diseasePharmacol Ther20081203 292 31618804122
   PubMed Web of Science ®Google Scholar
• NamsolleckPRecartiCFoulquierSSteckelingsUMUngerTAT2 receptor and tissue injury: therapeutic implicationsCurr Hypertens Res2014162 416 426
   Web of Science ®Google Scholar
• Bhaskar RaoAPrasadEDeepthiSSWound healing: a new perspective on glucosylated tetrahydrocurcuminDrug Des Devel Ther20159 3579 3588
   Web of Science ®Google Scholar
• PatelVBBodigaSBasuRLoss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axisCirc Res201211010 1322 133522474255
   PubMed Web of Science ®Google Scholar
• KokaVHuangXRChungAWangWSTruongLDLanHYAngiotensin II up-regulates angiotensin I converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathwayAm J Pathol20081725 1174 118318403595
   PubMed Web of Science ®Google Scholar
• BangaloreSFakheriRTokluBOgedegbeGWeintraubHMesserliFHAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trialsMayo Clin Proc2016911 51 6026763511
   PubMed Web of Science ®Google Scholar
• RamCVSAngiotensin receptor blockers: current status and future prospectsAm J Med20081218 656 66318691475
   PubMed Web of Science ®Google Scholar
• KikuchiKTancharoenSTakeshigeNThe efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular diseaseInt J Mol Sci2013147 13909 1393023880849
   PubMed Web of Science ®Google Scholar
• LapchakPAA critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?Expert Opin Pharmacother20101110 1753 176320491547
   PubMed Web of Science ®Google Scholar
• ZhangWGuoYYuSWeiJJinJEffects of edaravone on the expression of β-defensin-2 mRNA in lung tissue of rats with myocardial ischemia reperfusionMol Med Rep201375 1683 168723525405
   PubMed Web of Science ®Google Scholar
• TsujimotoIHikosoSYamaguchiOThe antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophyHypertension2005455 921 92615824197
   PubMed Web of Science ®Google Scholar
• ArumugamSThandavarayanRAVeeraveeduPTBeneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathyJ Cell Mol Med2012169 2176 218522268705
   PubMed Web of Science ®Google Scholar
• LiaoYIshikuraFBeppuSEchocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validationAm J Physiol20022825 H1703 H1708
   Google Scholar
• ZhaoZQPuskasJDXuDImprovement in cardiac function with small intestine extracellular matrix is associated with recruitment of c-kit cells, myofibroblasts, and macrophages after myocardial infarctionJ Am Coll Cardiol20105512 1250 126120298933
   PubMed Web of Science ®Google Scholar
• GargSDraznerMHRefining the classification of left ventricular hypertrophy to provide new insights into the progression from hypertension to heart failureCurr Opin Cardiol2016314 387 39327168169
   PubMed Web of Science ®Google Scholar
• BalakumarPJagadeeshGStructural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptorJ Mol Endocrinol2014532 R71 R9225013233
   PubMed Web of Science ®Google Scholar
• GuoLYinAZhangQZhongTO’RourkeSTSunCAngiotensin-(1–7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanismAm J Physiol20173125 H980 H991
   Google Scholar
• Nguyen Dinh CatAMontezanoACBurgerDTouyzRMAngiotensin II, NADPH oxidase, and redox signaling in the vasculatureAntioxid Redox Signal20131910 1110 112022530599
   PubMed Web of Science ®Google Scholar
• ImayamaIIchikiTInanagaKTelmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gammaCardiovasc Res2006721 184 19016938288
   PubMed Web of Science ®Google Scholar
• WermuthPJJimenezSAThe significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseasesClin Transl Med20154 225852818
   PubMed Web of Science ®Google Scholar
• KokaVXiaoRHChungACKWangWLuanDTHuiYLAngiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathwayAm J Pathol20081725 1174 118318403595
   PubMed Web of Science ®Google Scholar
• PatelVBZhongJCGrantMBOuditGYRole of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failureCirc Res20161188 1313 132627081112
   PubMed Web of Science ®Google Scholar
• WangNPErskineJZhangWWRecruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin IIJ Renin Angiotensin Aldosterone Syst2017182 1 14
   Web of Science ®Google Scholar
• KainDAmitUYagilCMacrophages dictate the progression and manifestation of hypertensive heart diseaseInt J Cardiol2016203 381 39526539962
   PubMed Web of Science ®Google Scholar
• HunyadyLCattKJPleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin IIMol Endocrinol2006205 953 97016141358
   PubMed Web of Science ®Google Scholar
• ZhangWChenDQQiFWangJXiaoWYZhuWZInhibition of calcium-calmodulin-dependent kinase II suppresses cardiac fibroblast proliferation and extracellular matrix secretionJ Cardiovasc Pharmacol2010551 96 10519935079
   PubMed Web of Science ®Google Scholar
• LeiBHitomiHMoriTEffect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblastsJ Pharmacol Sci20111172 98 10521897055
   PubMed Web of Science ®Google Scholar
• YuanSMJingHCardiac pathologies in relation to Smad-dependent pathwaysInteract Cardiovasc Thorac Surg2010114 455 46020650957
   PubMed Web of Science ®Google Scholar
• WangBOmarAAngelovskaTRegulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblastsAm J Physiol20072932 H1282 H1290
   Google Scholar
• KatzAMRolettELHeart failure: when form fails to follow functionEur Heart J2016375 449 45426497163
   PubMed Web of Science ®Google Scholar
• SzymanskiMKBuikemaJHvan VeldhuisenDJIncreased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial functionBasic Res Cardiol20121072 242 25622258067
   PubMed Web of Science ®Google Scholar
• SavinovaOVGerdesAMMyocyte changes in heart failureHeart Fail Clin201281 1 622108722
   PubMed Web of Science ®Google Scholar
• MatsumotoTWadaATsutamotoTOhnishiMIsonoTKinoshitaMChymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failureCirculation200310720 2555 255812742989
   PubMed Web of Science ®Google Scholar
• RyokeTGuYMaoLProgressive cardiac dysfunction and fibrosis in cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibitionCirculation199910016 1734 174310525494
   PubMed Web of Science ®Google Scholar
• LymperopoulosASturchlerEBathgate-SirykADifferent potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronismJ Am Coll Cardiol20146425 2805 280625541135
   PubMed Web of Science ®Google Scholar
• AbdAllaSLotherHAbdel-tawabAMQuittererUThe angiotensin II AT2 receptor is an AT1 receptor antagonistJ Biol Chem200127643 39721 3972611507095
   PubMed Web of Science ®Google Scholar
• DabulSBathgate-SirykAValeroTRSuppression of adrenal β-arrestin1-dependent aldosterone production by ARBs: head-to-head comparisonSci Rep20155 811625631300
   PubMed Web of Science ®Google Scholar
• ChouCHChenYHHungCSAldosterone impairs vascular smooth muscle function: from clinical to bench researchJ Clin Endocrinol Metab201510011 4339 434726401591
   PubMed Web of Science ®Google Scholar
• NappiJMSiegAAldosterone and aldosterone receptor antagonists in patients with chronic heart failureVasc Health Risk Manag20117 353 36321731887
   PubMedGoogle Scholar
• MedscapeFDA approves edaravone (Radicava) for amyotrophic lateral sclerosis Available from: http://www.medscape.com/viewarticle/879641Accessed May 5, 2017
   Google Scholar
• National Research CouncilGuide for the Care and Use of Laboratory Animals: Eighth EditionWashington DC, USAThe National Academies Press2011
   Google Scholar